Statins unmasking a mitochondrial myopathy: A case report and proposed mechanism of disease [4]

Southern Medical Journal

Volumn 96, Issue 3, 2003, Pages 318-320

  Diaczok, Benjamin J ^a,b   Shali, R ^a  

^a PROVIDENCE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESTYRAMINE; CREATINE KINASE; CYCLOSPORIN; DICLOFENAC; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; NICOTINIC ACID; PHENYTOIN; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE;

ADULT; CASE REPORT; CELL INCLUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ELECTROMYOGRAPHY; EXERCISE TEST; HUMAN; LETTER; MALE; MITOCHONDRIAL MYOPATHY; MOTOR NEUROPATHY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYALGIA; PERCEPTION DEAFNESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SENSORY NEUROPATHY; SHOULDER; SLOW MUSCLE FIBER; SYMPTOM;

EID: 0037345750     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000061501.81880.83     Document Type: Letter

References (16)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
2. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
5. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
6. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Aro J Cardiol 1994;74: 667-673.
7. Montgomery R, Conway TW, Spector AA, Chappell A. Biochemistry: A Case-Oriented Approach. St. Louis, Mosby-Year Book, 1996, ed 6.
8. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am 1997;277:40-47.
9. Pravachol, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 846-849.
10. Zocor, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 1917-1920.
11. Lipitor, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 2254-2257.
12. Lescol, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 2021-2024.
13. Mevacor, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 1833-1837.
14. Baycol, in Physicians' Desk Reference 2000. Montvale, NJ, Medical Economics Co., 2000, ed 54, pp 675-677.
15. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism - Monograph for physicians. Arch Intern Med 2000;160:2273-2280.
16. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. New York, McGraw-Hill Health Professions Division, 1998, ed 14.